COST-EFFECTIVENESS OF SEMAGLUTIDE 2.4 MG COMPARED WITH RESMETIROM AND STANDARD OF CARE FOR METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) IN THE U.S. USING MOST FAVORED NATION (MFN) PRICING
Author(s)
Aidan McGovern, MPH, MS1, Frank Cinfio, BS2, Aarth Sheth, PharmD1, Minseon Chung, PharmD, MPH, MS1, Roger Luo, PhD, MS1, Oliver Diaz, PhD, MS1, ARuth OMartinez, MS1, Husam Albarmawi, PhD1;
1Novo Nordisk Inc., Plainsboro, NJ, USA, 2Genesis Research Group, Hoboken, NJ, USA
1Novo Nordisk Inc., Plainsboro, NJ, USA, 2Genesis Research Group, Hoboken, NJ, USA
OBJECTIVES: Metabolic dysfunction‑associated steatohepatitis (MASH) is driven by metabolic, genetic, and environmental factors and is defined by hepatic steatosis with inflammation and hepatocellular injury. With progression, inflammation and injury can cause fibrosis and cirrhosis, which ultimately result in a higher risk of developing costly adverse liver events such as hepatocellular carcinoma, liver failure, and liver transplantation. Although underdiagnosed, the prevalence of MASH is rising in the U.S. system. This analysis evaluated the cost-effectiveness of semaglutide using the most favored nation (MFN) price compared with standard of care (SoC) and resmetirom.
METHODS: A CEM using a Markov cohort structure analyzed fibrosis progression and comorbidities over a lifetime horizon from a U.S. healthcare system perspective. The framework captured disease progression through health states sourced from clinical trials and literature including fibrosis stages, compensated and decompensated cirrhosis, hepatocellular carcinoma (HCC), liver transplant, and death. The analysis incorporated direct medical costs and health outcomes, consistent with ISPOR good practice recommendations for cost-effectiveness modeling. For this analysis, the MFN price of $350 per month for semaglutide was used. Health outcomes were measured in life years, QALY, and evLYGs (equal value life year gained) and a 3% discount was applied.
RESULTS: Treatment with semaglutide was associated with substantial cost savings compared with resmetirom 80 mg (−$526,189), resmetirom 100 mg (−$357,070), and SoC (−$111,079). Semaglutide generated 15.37 life-years (LYs) and 11.00 quality-adjusted life-years (QALYs), exceeding all comparators. Compared with resmetirom and SoC, semaglutide was the dominant strategy, with lower costs and greater health benefits across outcomes assessed, including LYs, QALYs, and evLYGs.
CONCLUSIONS: Under MFN pricing, semaglutide was associated with lower costs and improved health outcomes compared with resmetirom and SoC from a U.S. healthcare system perspective. These findings suggest that semaglutide demonstrates favorable cost-effectiveness in this analysis.
METHODS: A CEM using a Markov cohort structure analyzed fibrosis progression and comorbidities over a lifetime horizon from a U.S. healthcare system perspective. The framework captured disease progression through health states sourced from clinical trials and literature including fibrosis stages, compensated and decompensated cirrhosis, hepatocellular carcinoma (HCC), liver transplant, and death. The analysis incorporated direct medical costs and health outcomes, consistent with ISPOR good practice recommendations for cost-effectiveness modeling. For this analysis, the MFN price of $350 per month for semaglutide was used. Health outcomes were measured in life years, QALY, and evLYGs (equal value life year gained) and a 3% discount was applied.
RESULTS: Treatment with semaglutide was associated with substantial cost savings compared with resmetirom 80 mg (−$526,189), resmetirom 100 mg (−$357,070), and SoC (−$111,079). Semaglutide generated 15.37 life-years (LYs) and 11.00 quality-adjusted life-years (QALYs), exceeding all comparators. Compared with resmetirom and SoC, semaglutide was the dominant strategy, with lower costs and greater health benefits across outcomes assessed, including LYs, QALYs, and evLYGs.
CONCLUSIONS: Under MFN pricing, semaglutide was associated with lower costs and improved health outcomes compared with resmetirom and SoC from a U.S. healthcare system perspective. These findings suggest that semaglutide demonstrates favorable cost-effectiveness in this analysis.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
EE219
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
SDC: Cardiovascular Disorders (including MI, Stroke, Circulatory), SDC: Diabetes/Endocrine/Metabolic Disorders (including obesity), SDC: Gastrointestinal Disorders, SDC: Geriatrics